Galapagos and Blood Centers of America announce strategic collaboration to accelerate Galapagos’ decentralized CAR-T manufacturing network in the U.S.
- BCA’s national network of blood centers will provide decentralized manufacturing services for
Galapagos’ CAR-T product candidates, close to cancer treatment centers - Collaboration enables rapid deployment of Galapagos’ decentralized CAR-T platform across the U.S., improving patient access to potentially life-saving CAR-T treatments
- Important milestone for Galapagos’ U.S. expansion strategy, supporting upcoming pivotal trials and potential future commercial manufacturing of CAR-T therapies
- Complements existing collaborations with Galapagos’ other manufacturing partners
